Compare GIFT & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GIFT | NRSN |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.6M | 29.8M |
| IPO Year | N/A | 2021 |
| Metric | GIFT | NRSN |
|---|---|---|
| Price | $1.08 | $0.90 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $4.00 | ★ $14.00 |
| AVG Volume (30 Days) | 26.5K | ★ 433.4K |
| Earning Date | 11-10-2025 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $86,142,442.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.82 | $0.81 |
| 52 Week High | $2.38 | $2.60 |
| Indicator | GIFT | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 47.77 | 36.61 |
| Support Level | $1.07 | $1.07 |
| Resistance Level | $1.14 | $1.24 |
| Average True Range (ATR) | 0.05 | 0.12 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 27.78 | 1.53 |
Giftify Inc through its wholly-owned subsidiary, has been in the business of connecting digital consumers, businesses and communities with dining and merchant deal options throughout the United States. The company connects digital consumers, businesses, and communities offering dining and merchant deal options nationwide restaurants, and retailers to customers. The Company buys merchant gift cards from the general public and distributors at a discount and then resells them at a markup.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.